Quantum Biopharma (NASDAQ:QNTM) Downgraded by Wall Street Zen to “Sell”

Quantum Biopharma (NASDAQ:QNTM) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

Quantum Biopharma Stock Performance

Shares of Quantum Biopharma stock opened at $6.18 on Friday. Quantum Biopharma has a 52-week low of $2.89 and a 52-week high of $38.25. The company has a fifty day moving average of $8.14 and a 200-day moving average of $14.20. The stock has a market capitalization of $23.61 million, a price-to-earnings ratio of -0.57 and a beta of 0.24.

Quantum Biopharma (NASDAQ:QNTM) last issued its earnings results on Friday, November 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05). On average, equities research analysts forecast that Quantum Biopharma will post -3.27 earnings per share for the current fiscal year.

Institutional Trading of Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Steward Partners Investment Advisory LLC purchased a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned about 0.11% of Quantum Biopharma as of its most recent SEC filing. 1.24% of the stock is currently owned by hedge funds and other institutional investors.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.